Ipsen appoints Keira Driansky as EVP, President of North America

PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership Team (ELT) and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew.

“We are thrilled to welcome Keira to Ipsen as our new President of North America as she brings extensive experience in the life sciences industry and a proven track record of leadership to our team,” said David Loew, CEO Ipsen. “As we continue to navigate the complexities of the pharmaceutical landscape, Keira’s strategic vision will be instrumental in guiding our company toward a future of bringing groundbreaking medicines and enhanced outcomes to patients.”

Keira will be joining Ipsen from AstraZeneca, where she spent the last 13 years leading teams across the US, Europe and global functions. Most recently Keira served as Country President of AstraZeneca for Belgium and Luxembourg, where she oversaw 14 launches across various therapeutic areas, leading AZ to become the fastest-growing pharma company in Belgium. Previously, she served as VP, Global Commercial Head for Tagrisso across more than 90 countries. She also spent more than five years in AZ’s US Oncology business leading multiple sales and marketing teams through six launches.  

A former science researcher, Keira brings broad experience across the healthcare industry, from commercial leadership to healthcare investing and business development. She received her MBA from Harvard Business School and an MPhil in Bioscience Enterprise from the University of Cambridge. Keira also conducted breast cancer epidemiology research at the University of Oxford as a Marshall Scholar and conducted biochemistry research at Yale under a Howard Hughes Medical Fellowship.

“I’m excited to join the talented and established team at Ipsen at this time of dynamic growth, with four innovative launches across therapeutic areas, including the latest in first-line pancreatic cancer,” said Keira Driansky. “I look forward to partnering with Ipsen’s employees, customers, and stakeholders across the healthcare ecosystem to deliver breakthrough solutions for some of the most pressing global health challenges of our time."

Stewart Campbell, who as Ipsen’s President of North America for three years led the acceleration of Ipsen’s growth, will leave Ipsen to pursue other opportunities.

ENDS

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen contacts

Investors

• Craig Marks | +44 (0)7584 349 193 | craig.marks@ipsen.com
• Nicolas Bogler | +33 6 52 19 98 92 | nicolas.bogler@ipsen.com

Media

• Amy Wolf | +41 79 576 07 23 | amy.wolf@ipsen.com
• Elizabeth Kalina | +1 857 331 0060| elizabeth.kalina@ipsen.com

Disclaimers and/or Forward-Looking Statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.

Attachment

• Ipsen PR_Keira Driansky_02052024

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.